Published in:
01-09-2003 | Article
Pyruvate inhibits zinc-mediated pancreatic islet cell death and diabetes
Authors:
I. Chang, N. Cho, J.-Y. Koh, M.-S. Lee, MD PhD
Published in:
Diabetologia
|
Issue 9/2003
Login to get access
Abstract
Aims/hypothesis
We have shown that zinc ion (Zn2+) in secretory granules of pancreatic beta cells could act as a paracrine death effector in streptozotocin-induced diabetes. As Zn2+ has been reported to perturb glycolysis, we studied if pyruvate could inhibit Zn2+-mediated islet cell death in vitro and streptozotocin-induced diabetes in vivo by normalizing intracellular energy metabolism.
Methods
Cell death was measured by quantitative viable cell staining and Hoechst/propidium iodide staining. ATP was measured by bioluminescence determination. Pyruvate was infused through the tail vein 1 h before streptozotocin administration. Beta-cell volume was measured by point counting of the insulin-containing cells.
Results
Zn2+ induced classical necrosis on MIN6N8 insulinoma cells which was associated with a rapid decline of intracellular ATP levels. Pyruvate inhibited Zn2+-induced necrosis of insulinoma cells and depletion of intracellular ATP by Zn2+. Pyruvate did not inhibit other types of necrosis or apoptosis. Energy substrates such as oxaloacetate, α-ketoglutarate and succinic acid dimethylester also attenuated Zn2+-induced insulinoma cell death. Methylpyruvate that does not generate NAD+ in the cytoplasm or α-ketoisocaproate that stimulates ATP generation exclusively in mitochondria also protected insulinoma cells from Zn2+-induced necrosis. Pyruvate infusion inhibited the development of diabetes by protecting beta-cell mass after streptozotocin administration.
Conclusion/interpretation
These results indicate that pyruvate inhibits Zn2+-induced necrosis of beta cells in vitro by protecting intracellular ATP levels and also streptozotocin-induced diabetes in vivo where Zn2+ has been reported to act as a paracrine death effector.